Journal
JOURNAL OF ORGANIC CHEMISTRY
Volume 83, Issue 11, Pages 6066-6085Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.joc.8b00728
Keywords
-
Categories
Funding
- NSF [DGE-1144469, CAREER-1057143]
- SNF [PBZHP2-147311]
- American Cancer Society
- Research Corporation Cottrell Scholars program
- DuPont
- NIH [5T32GM007616-39]
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007616] Funding Source: NIH RePORTER
Ask authors/readers for more resources
(+)-Psiguadial B is a diformyl phloroglucinol meroterpenoid that exhibits antiproliferative activity against the HepG2 human hepatoma cancer cell line. This full account details the evolution of a strategy that culminated in the first enantioselective total synthesis of (+)-psiguadial B. A key feature of the synthesis is the construction of the transcyclobutane motif by a Wolff rearrangement with in situ catalytic, asymmetric trapping of the ketene. An investigation of the substrate scope of this method to prepare enantioenriched 8-aminoquinolinamides is disclosed. Three routes toward (+)-psiguadial B were evaluated that featured the following key steps: (1) an ortho-quinone methide hetero-Diels-Alder cycloaddition to prepare the chroman framework, (2) a Prins cyclization to form the bridging bicyclo[4.3.1]decane system, and (3) a modified Norrish Yang cyclization to generate the chroman. Ultimately, the successful strategy employed a ring-closing metathesis to form the seven-membered ring and an intramolecular O-arylation reaction to complete the polycyclic framework of the natural product.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available